Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274287 · ClinicalTrials.gov registry record · Phase 2
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
A Phase 2 study, sponsored by Oncology Specialists, S.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00274287 is a Phase 2 study that has completed, run by Oncology Specialists, S.C.. The registered enrollment target is 15 participants.
The verdict
NCT00274287, a Phase 2 study, has completed, sponsored by Oncology Specialists, S.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other chemotherapy schedule.
Interventions
- DRUG GM CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274287
The ClinicalTrials.gov registry entry for NCT00274287 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GM CSF is the first listed.
NCT00274287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274287 about?
NCT00274287 is a clinical study titled "GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere". This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other chemotherapy schedule.
What is the current status of trial NCT00274287?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00274287?
The interventions under investigation include: GM CSF (DRUG).
Who is sponsoring clinical trial NCT00274287?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.